Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

Phase 2 Active, not recruiting NCT03896503

Summary

This phase II trial studies how well berzosertib (M6620) works when given in combination with topotecan hydrochloride (topotecan) compared with topotecan alone in treating patients with small cell lung cancer that has come back (relapsed), or small cell cancer that arises from a site other than the lung (extrapulmonary). Drugs used in chemotherapy, such as topotecan hydrochloride, work by damaging the DNA (deoxyribonucleic acid) in tumor cells, causing those cells to die and the tumor to shrink. However, some tumor cells can become less affected by chemotherapy because they have ways to repair the damaged DNA. The addition of M6620 could help topotecan hydrochloride shrink the cancer and prevent it from returning by blocking enzymes needed for DNA repair.

Progression-free Survival (PFS) Reported With 80% Confidence Interval

From start of treatment to time of progression or death, whichever occurs first, assessed at 6 months after last participant has enrolled; up to 2 years for pulmonary cohort and up 31.5 months for Exploratory Cohort. · Months

Progression-free Survival (PFS) Reported With 95% Confidence Interval

From start of treatment to time of progression or death, whichever occurs first, assessed at 6 months after last participant has enrolled; up to 2 years for pulmonary cohort and up 31.5 months for Exploratory Cohort. · Months

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

• Risk and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer — M.D. Anderson Cancer Center
• Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tum — National Cancer Institute (NCI)
• Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients W — National Cancer Institute (NCI)
• A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients W — AstraZeneca
• Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therap — National Cancer Institute (NCI)
• Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With — National Cancer Institute (NCI)

All trials